Full Press Release Details
MARLBOROUGH, Mass. , Aug. 2, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for single-use duodenoscopes, applicable to the EXALT™ Model D Single-Use Duodenoscope, as part of its Fiscal Year 2022 Hospital Inpatient Prospective Payment System. NTAP was created to facilitate patient access for qualifying new medical technologies that substantially improve the diagnosis or treatment of Medicare beneficiaries. Beginning October 1, 2021 , CMS will provide hospitals with additional device reimbursement when the EXALT Model D Single-Use Duodenoscope is used for eligible cases in the hospital inpatient setting.
The EXALT Model D Single-Use Duodenoscope is designed to eliminate the risk of infection due to ineffective reprocessing of traditional reusable duodenoscopes. Duodenoscopes are used to diagnose and treat various pancreatic and biliary conditions during endoscopic retrograde cholangiopancreatography (ERCP) procedures. Every year, more than 700,000 ERCP procedures are performed in the U.S. and approximately 1.5 million are completed worldwide. i In 2019 the U.S. Food and Drug Administration (FDA) recommended that providers utilize duodenoscopes with disposable components or fully disposable devices, when available. ii
The EXALT Model D Single-Use Duodenoscope previously received Breakthrough Device Designation from the FDA as well as transitional pass-through (TPT) payment by CMS, the latter of which allows for incremental device reimbursement for Medicare cases performed in the hospital outpatient setting. Further, in response to a Boston Scientific request, CMS created two unique ICD-10 procedure codes for hospitals to facilitate reporting the use of single-use duodenoscopes when used in the hospital inpatient setting beginning October 1, 2021 .
The EXALT Model D Duodenoscope is part of the Boston Scientific single-use device portfolio, which includes technologies within the gastrointestinal, pancreaticobiliary, surgical, urological and airway spaces such as the LithoVue™ Digital Flexible Ureteroscope , SpyGlass™ DS Direct Visualization System , SpyGlass™ Discover Digital Catheter , and EXALT™ Model B Single-Use Bronchoscope . iii
For additional information, please visit the EXALT Model D Single-Use Duodenoscope page on the Boston Scientific website.
About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook .
Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend," and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, clinical trials and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Nate Illsley Media Relations (508) 269-4607 (office) [email protected]
Lauren Tengler Investor Relations 508-683-4479 [email protected]
i Internal estimate ii United States Food and Drug Administration website: " The FDA is Recommending Transition to Duodenoscopes with Innovative Designs to Enhance Safety: FDA Safety Communication" April 10, 2020 iii The EXALT Model B Single-Use Bronchoscope is currently pending FDA 510(k) review and is not yet available for sale in the United States
SOURCE Boston Scientific Corporation